Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Effect on Telotristat Etiprate PK
NCT02195635Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telotristat ethyl in Carcinoid Syndrome (CS), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Plasma concentrations of telotristat ethyl at Day 8 and Plasma concentrations of metabolite LP-778902 at Day 8. Started Jul 2014; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT02195635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195635.